Resultados de la búsqueda 71-80 of 10983 for Linaclotide

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients ...

  4. The world's best hospital - Mayo Clinic

    Mayo Clinic is the No. 1 hospital in the world., with campuses in Arizona, Florida, and Minnesota.

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  6. Hematología - Ensayos clínicos - Mayo Clinic

    Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Probiotics Preventing Immune Checkpoint Inhibitor-Induced Colitis · To evaluate the safety of multi-strain probiotic blend in cancer patients receiving ICIs. · To ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    To evaluate the safety of multi-strain probiotic blend in cancer patients receiving ICIs. · To evaluate the clinical outcomes related to IIC, including the ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    To evaluate the safety of multi-strain probiotic blend in cancer patients receiving ICIs. · To evaluate the clinical outcomes related to IIC, including the ...